Gonal-f RFF Pen

See also: Generic Gonal-f, Generic Gonal-f RFF

Gonal-f RFF Pen is a brand name of follicle stimulating hormone, approved by the FDA in the following formulation(s):

GONAL-F RFF PEN (follitropin alfa/beta - injectable; subcutaneous)

• 
  Manufacturer: EMD SERONO
  
  Approval date: May 25, 2004
  
  Strength(s): 300 IU/0.5ML ^[RLD], 450 IU/0.75ML ^[RLD], 900 IU/1.5ML ^[RLD]

Has a generic version of Gonal-f RFF Pen been approved?

No. There is currently no therapeutically equivalent version of Gonal-f RFF Pen available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gonal-f RFF Pen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Follicle stimulating hormone and pharmaceutical compositions containing same
  Patent 5,767,067
  Issued: June 16, 1998
  Inventor(s): Arpaia; Guiseppe & Serani; Serenella & Sirna; Antonino & Villa; Stefano
  Assignee(s): Istituto di Ricerca Cesare Serono S.p.A.
  Purification of human FSH from post-menopausal urine gonadogropin using immunochromatography and reverse phase HPLC steps yelds a biologically active hormone which is free from detectable traces of LH and other urinary proteins.
  
  Patent expiration dates:
  
  
  • June 16, 2015
    
    ✓ 
    Drug substance
  
  



• 
  Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof
  Patent 5,767,251
  Issued: June 16, 1998
  Inventor(s): Reddy; Vermuri B. & Hsiung; Nancy & Beck; Anton K. & Bernstine; Edward George
  Assignee(s): Genzyme Corporation
  Biologically active heterodimeric human fertility hormones composed of two different subunits, each subunit being synthesized in the same cell transformed by at least one cell expression vector having heterologous DNA encoding each subunit with each subunit being controlled by a separate promoter. Preferred human fertility hormones include hCG, hLH and hFSH.
  
  Patent expiration dates:
  
  
  • June 16, 2015
    
    ✓ 
    Drug substance
  
  



• 
  FSH formulation
  Patent 7,446,090
  Issued: November 4, 2008
  Inventor(s): Hoffmann; James Arthur & Lu; Jirong
  Assignee(s): Ares Trading S.A.
  This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had previously existed having such extended use indications. These products are particularly useful in therapeutic regimens for increasing serum levels of FSH or a FSH variant over a period of treatment. Thus, inter alia, the invention fills the need for convenient products of FSH or from a FSH variant.
  
  Patent expiration dates:
  
  
  • August 23, 2019
    
    ✓ 
    Drug product
  
  



• 
  Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
  Patent 7,741,268
  Issued: June 22, 2010
  Inventor(s): Samaritani; Fabrizio & Donati; Piergiorgio
  Assignee(s): Ares Trading S.A.
  The invention relates to the field of pharmaceutical formulations of follicle-stimulating hormone (FSH), luteinising hormone (LH), and mixtures of FSH and luteinising hormone (LH), and to methods of producing such formulations. The invention provides a liquid or freeze-dried formulation of FSH, or LH, or FSH and LH comprising a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68.
  
  Patent expiration dates:
  
  
  • April 2, 2024
    
    ✓ 
    Drug product
  
  

See also...

• Gonal-f RFF Pen Solution Consumer Information (Wolters Kluwer)
• Gonal-f RFF Pen Consumer Information (Cerner Multum)
• Follitropin Alfa Powder Consumer Information (Wolters Kluwer)
• Follitropin Alfa Solution Consumer Information (Wolters Kluwer)
• Follitropin Beta Consumer Information (Wolters Kluwer)
• Follicle stimulating hormone Consumer Information (Cerner Multum)
• Follitropin alfa Subcutaneous Advanced Consumer Information (Micromedex)
• Follitropin beta Subcutaneous Advanced Consumer Information (Micromedex)